Catalyst Pharmaceuticals, Inc. Stock price

Equities

CPRX

US14888U1016

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
15.94 USD -2.03% Intraday chart for Catalyst Pharmaceuticals, Inc. -4.09% -5.18%
Sales 2024 * 464M Sales 2025 * 553M Capitalization 1.92B
Net income 2024 * 138M Net income 2025 * 186M EV / Sales 2024 * 3.15 x
Net cash position 2024 * 459M Net cash position 2025 * 682M EV / Sales 2025 * 2.23 x
P/E ratio 2024 *
14 x
P/E ratio 2025 *
10.6 x
Employees 167
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.59%
More Fundamentals * Assessed data
Dynamic Chart
Citigroup Starts Coverage on Catalyst Pharmaceuticals With Buy Rating, $27 Price Target MT
Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE(R) (Vamorolone) in the United States DJ
Catalyst Pharmaceuticals' Agamree Now Available in US to Treat Duchenne Muscular Dystrophy MT
Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy CI
Transcript : Catalyst Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 01:35 PM
Catalyst Pharmaceuticals Receives Buy Rating From BofA on Track Record for License, Acquisition Deals MT
BofA Securities Initiates Catalyst Pharmaceuticals With Buy Rating, Price Target is $23 MT
Cantor Fitzgerald Raises Catalyst Pharmaceuticals' Price Target to $34 From $27, Maintains Overweight Rating MT
Transcript : Catalyst Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 29, 2024
Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024 CI
Catalyst Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Catalyst Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Catalyst Pharmaceuticals Seeks Acquisitions CI
Catalyst Pharmaceuticals Raises $140.1 Million From Share Offering MT
Top Stories at Midday: December US Nonfarm Payrolls Rise; ISM US Services Index Falls; CVS Names Finance Chief; Tesla to Recall Vehicles in China; Catalyst Prices Stock Offering MT
More news
1 day+3.30%
1 week-3.78%
Current month+1.50%
1 month+13.38%
3 months-5.90%
6 months+33.69%
Current year-3.21%
More quotes
1 week
15.67
Extreme 15.6701
16.67
1 month
15.28
Extreme 15.28
17.50
Current year
13.12
Extreme 13.1161
17.50
1 year
11.09
Extreme 11.09
18.22
3 years
4.16
Extreme 4.16
22.11
5 years
2.23
Extreme 2.232
22.11
10 years
0.51
Extreme 0.51
22.11
More quotes
Managers TitleAgeSince
Founder 77 01-12-31
Chief Executive Officer 62 15-02-18
Director of Finance/CFO 53 Dec. 31
Members of the board TitleAgeSince
Founder 77 01-12-31
Director/Board Member 78 15-02-18
Director/Board Member 60 02-09-30
More insiders
Date Price Change Volume
24-03-28 15.94 -2.03% 1 171 474
24-03-27 16.27 +3.30% 1,471,658
24-03-26 15.75 -0.69% 828,267
24-03-25 15.86 +0.83% 1,085,212
24-03-22 15.73 -5.35% 948,460

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With the patient focus, the Company is engaged in developing a robust pipeline of cutting-edge, medicines for rare diseases. The Company's New Drug Application for FIRDAPSE (amifampridine) tablets 10 milligrams (mg) for the treatment of adults with Lambert-Eaton myasthenic syndrome (LEMS). The Company's FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. The Company also has FYCOMPA (perampanel) CIII, a prescription medicine approved in people with epilepsy aged four and older alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures and with other medicines to treat primary generalized tonic-clonic seizures for people with epilepsy aged 12 and older.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
16.27 USD
Average target price
26.86 USD
Spread / Average Target
+65.07%
Consensus
  1. Stock
  2. Equities
  3. Stock Catalyst Pharmaceuticals, Inc. - Nasdaq